ahro_8k-012313.htm
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.  20549
 
 
FORM 8-K
 
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
 
Date of Report:
(Date of earliest event reported)
 
January 23, 2013
 
ATHERONOVA INC.
(Exact name of registrant as specified in charter)
 
Delaware
(State or other Jurisdiction of Incorporation or Organization)
 

000-52315
(Commission File Number)
  
20-1915083
(IRS Employer Identification No.)
 
2301 Dupont Drive, Suite 525
Irvine, CA 92612
(Address of Principal Executive Offices and zip code)
  

(949) 476-1100
(Registrant’s telephone
number, including area code)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions:
 
[  ]  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[  ]  Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12(b))
[  ]  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[  ]  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 
 
 

Item 7.01.              Regulation FD Disclosure.
 
On January 23, 2103, Thomas W. Gardner, the Registrant’s Chief Executive Officer, will participate in the Noble Financial Capital Markets’ Ninth Annual Equity Conference to be held in Hollywood, Florida.  A copy of Mr. Gardner’s presentation is being furnished as Exhibit 99.1 to this report and is incorporated herein by reference.
 
Item 9.01.              Financial Statements and Exhibits
 
(d)           Exhibits.
 
The following exhibits are filed herewith:
 
Exhibit
Number                      Description
 
                                99.1                             AtheroNova Inc. Investor Presentation.*
 
* Furnished, not filed.
 
 
 
 
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
  AtheroNova Inc.  
     
       
Date:  January 23, 2013
By:
/s/ Mark Selawski  
    Mark Selawski  
    Chief Financial Officer & Secretary  
       
 
 
3